Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP885
- Development stage
- Preclinical
- Lead developer
- RESprotect
- Modality
- Small Molecules
01
Overview
RP885 is a preclinical-stage small molecule drug candidate developed by RESprotect. It is designed to target Heat Shock Protein 27 (Hsp27), a molecular chaperone that is frequently overexpressed in various cancers and is associated with treatment resistance, anti-apoptotic signaling, and poor clinical outcomes. By inhibiting Hsp27, RP885 aims to disrupt the protective mechanisms of tumor cells, potentially sensitizing them to chemotherapy and other standard-of-care treatments. The drug is currently being investigated as a potential therapy for cancer, specifically focusing on overcoming multi-drug resistance in oncology.
02
Targets
HSPB1 (Heat shock protein beta-1)
Beyond the preview
Go deeper on RP885.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP885.